Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Amortization of Deferred Charges (2022 - 2023)

Whitehawk Therapeutics (WHWK) has disclosed Amortization of Deferred Charges for 2 consecutive years, with -$486000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Amortization of Deferred Charges rose 54.41% to -$486000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was -$2.3 million, a N/A change, with the full-year FY2023 number at -$3.1 million, down 158.11% from a year prior.
  • Amortization of Deferred Charges was -$486000.0 for Q4 2023 at Whitehawk Therapeutics, up from -$588000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of -$149000.0 in Q3 2022 to a low of -$1.1 million in Q4 2022.